Alan Robert Saltiel | |
---|---|
Born | |
Education | Duke University University of North Carolina |
Scientific career | |
Institutions | Parke-Davis Warner-Lambert Company University of Michigan Rockefeller University, New York University of California, San Diego |
Doctoral advisor | Shihadeh N. Nayfeh |
Other academic advisors | Pedro Cuatrecasas |
Alan Robert Saltiel (born November 29, 1953) is an American endocrinologist and biochemist. He is Distinguished Professor of Medicine and Pharmacology, holds the Maryam Ahmadian Endowed Chair in Metabolic Health, the Director of the UCSD/UCLA Diabetes Research Center and Director of the Institute for Diabetes and Metabolic Health at the University of California, San Diego.
Saltiel was born in New Brunswick, New Jersey, US. He holds an AB from Duke University (1975) in zoology and a Ph.D. from the University of North Carolina (1980) in biochemistry. [1]
During his doctorate studies in biochemistry at the University of North Carolina, Saltiel worked on thyroid-stimulating hormone and its relationship to thyroid cancer. As a post-doctoral fellow under Pedro Cuatrecasas in the Wellcome Research Laboratories, he began investigating insulin. He was distinguished research fellow and senior director of the department of cell biology at Parke-Davis Pharmaceutical Research Division (now Pfizer Global Research). In addition to having published more than 320 research papers, Saltiel holds 19 patents and has extensive experience with the FDA's testing and approval process for new drugs.
Saltiel was the Mary Sue Coleman Director of the Life Sciences Institute at the University of Michigan; a professor at the Division of Molecular Medicine and Genetics at the University of Michigan Medical School; a faculty member at the Michigan Diabetes Research and Training Center; and John Jacob Abel Professor of Life Sciences, Department of Molecular and Integrative Physiology; a member of the Steering Committee Member at the Center for Advancing Research & Solutions for Society. [2] He served as the director of the Life Sciences Institute from 2001 to 2015. [3] He was also a John Jacob Abel Collegiate Professor of the Life Sciences at the Department of Molecular & Integrative Physiology at the UM Medical School. [4]
Saltiel's lab researches signaling pathways in insulin action. [5] Such research is aimed at identifying the various ways in which problems with the insulin signaling pathway trigger diabetes. [6] Researchers in the lab have also uncovered new hormone signaling pathways and the role that proteins and genes play in this process. [6] These discoveries may reveal how the insulin-glucose balance necessary for the survival of the cell is lost due to obesity in those with diabetes. [2] [6]
Saltiel has received many awards over the course of his career, including the Rosalyn Yalow Research and Development Award from the American Diabetes Association, Hirschl Award, The John Jacob Abel Award from ASPET and The Goodman and Gilman and Pharmacia Awards, also from ASPET. [7] He is a member of the National Academy of Medicine and fellow of the American Association for the Advancement of Science. His work is often cited in biochemistry literature, [7] with more than 73,000 citations as of October 2024. [8]
His true dream is to star for the New York Knicks. [9]
Endocrinology is a branch of biology and medicine dealing with the endocrine system, its diseases, and its specific secretions known as hormones. It is also concerned with the integration of developmental events proliferation, growth, and differentiation, and the psychological or behavioral activities of metabolism, growth and development, tissue function, sleep, digestion, respiration, excretion, mood, stress, lactation, movement, reproduction, and sensory perception caused by hormones. Specializations include behavioral endocrinology and comparative endocrinology.
Ronald Mark Evans is an American Biologist, Professor and Head of the Salk’s Gene Expression Laboratory, and the March of Dimes Chair in Molecular and Developmental Biology at the Salk Institute for Biological Studies in La Jolla, California and a Howard Hughes Medical Institute Investigator. Dr. Ronald M. Evans is known for his original discoveries of nuclear hormone receptors (NR), a special class of transcriptional factor, and the elucidation of their universal mechanism of action, a process that governs how lipophilic hormones and drugs regulate virtually every developmental and metabolic pathway in animals and humans. Nowadays, NRs are among the most widely investigated group of pharmaceutical targets in the world, already yielding benefits in drug discovery for cancer, muscular dystrophies, osteoporosis, type II diabetes, obesity, and cardiovascular diseases. His current research focuses on the function of nuclear hormone signaling and their function in metabolism and cancer.
John Jacob Abel was an American biochemist and pharmacologist. He established the pharmacology department at Johns Hopkins University School of Medicine in 1893, and then became America's first full-time professor of pharmacology. During his time at Hopkins, he made several important medical advancements, especially in the field of hormone extraction. In addition to his laboratory work, he founded several significant scientific journals such as the Journal of Biological Chemistry and the Journal of Pharmacology and Experimental Therapeutics.
The Kolling Institute is located in the grounds of the Royal North Shore Hospital in St Leonards, Sydney Australia. The institute, founded in 1920, is the oldest medical research institute in New South Wales.
David Ernest James is a cell biologist who discovered the glucose transporter GLUT4. He has also been responsible for the molecular dissection of the intracellular trafficking pathways that regulate GLUT4 translocation to the cell surface, the topological mapping of the insulin signal transduction pathway, the creation of a method for studying in vivo metabolism in small animals, and the use of this method to gain insights into whole-animal fuel metabolism and homeostasis.
Kenneth B. Storey is a Canadian scientist whose work draws from a variety of fields including biochemistry and molecular biology. He is a Professor of Biology, Biochemistry and Chemistry at Carleton University in Ottawa, Canada. Storey has a world-wide reputation for his research on biochemical adaptation - the molecular mechanisms that allow animals to adapt to and endure severe environmental stresses such as deep cold, oxygen deprivation, and desiccation.
Lewis C. Cantley is an American cell biologist and biochemist who has made significant advances to the understanding of cancer metabolism. Among his most notable contributions are the discovery and study of the enzyme PI-3-kinase, now known to be important to understanding cancer and diabetes mellitus. He is currently Meyer Director and Professor of Cancer Biology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York City. He was formerly a professor in the Departments of Systems Biology and Medicine at Harvard Medical School, and the Director of Cancer Research at the Beth Israel Deaconess Medical Center, in Boston, Massachusetts. In 2016, he was elected Chairman of the Board for the Hope Funds for Cancer Research.
Mitchell Lazar is an endocrinologist and physician-scientist known for his discovery of the hormone resistin and his contributions to the transcriptional regulation of metabolism.
Sir Stephen Patrick O'Rahilly is an Irish-British physician and scientist known for his research into the molecular pathogenesis of human obesity, insulin resistance and related metabolic and endocrine disorders.
Carl Ronald Kahn is an American physician and scientist, best known for his work with insulin receptors and insulin resistance in diabetes and obesity. He is the Chief Academic Officer at Joslin Diabetes Center, the Mary K. Iacocca Professor of Medicine at Harvard Medical School and a member of the National Academy of Sciences since 1999.
Michel Bouvier is a Canadian biochemist and molecular pharmacologist. He is a professor of biochemistry and molecular medicine at Université de Montréal; a principal investigator and the chief executive officer at the Institute for Research in Immunology and Cancer; and an associate vice-president in Research, Scientific Discovery, Creation, and Innovation at Université de Montréal. His work focuses on the study of cell signaling towards the discovery of new pharmaceutical drugs.
Roger D. Cone is the Mary Sue Coleman Director of the Life Sciences Institute and the Vice Provost for the Biosciences Initiative at the University of Michigan; a member of the editorial board for the journal Cell Metabolism; and a member of the National Academies of Sciences and Medicine. He is a noted researcher in the biological underpinnings of obesity, anorexia, cachexia and other eating and metabolic disorders.
Gökhan S. Hotamisligil is a Turkish-American physician scientist; James Stevens Simmons Chair of Genetics and Metabolism at Harvard T.H. Chan School of Public Health (HSPH); Director of the Sabri Ülker Center for Metabolic Research and associate member of Harvard-MIT Broad Institute, Harvard Stem Cell Institute and the Joslin Diabetes Center.
Vengalil Krishna Kumar Chatterjee is a British endocrinologist. He is a professor of endocrinology in the Department of Medicine at the University of Cambridge and a fellow of Churchill College, Cambridge. He is also the director of the Cambridge Clinical Research Centre, part of the National Institute for Health Research (NIHR).
Namandjé N. Bumpus is an American pharmacologist who serves as the Principal Deputy Commissioner and Acting Chief Scientist of the Food and Drug Administration. She was previously director of the department of pharmacology and molecular sciences at Johns Hopkins University School of Medicine, where she holds the E.K. Marshall and Thomas H. Maren professorship in pharmacology. Bumpus is known for her research on the metabolism of antiviral drugs used to treat HIV-1 and how genetic variations in drug-processing enzymes may impact these drugs' efficacy. Bumpus received a Presidential Early Career Award for Scientists and Engineers in 2016. The Food and Drug Administration’s top scientist Namandjé Bumpus has assumed the role of principal deputy commissioner when longtime agency leader Janet Woodcock retired from that role in January 2024.
Antonio Vidal-Puig is a Spanish medical doctor and scientist who works as a Professor of Molecular Nutrition and Metabolism at the University of Cambridge (UK), best known for advancing the concept that pharmacological targeting of brown fat may serve to treat overweight and obesity in affected individuals, as well as for introducing the concept of adipose tissue "expandability" as an important factor in the pathogenesis of insulin resistance in the context of positive energy balance. His published work focuses on areas such as adipose tissue metabolism and lipotoxicity, regulation of insulin secretion, and the pathophysiology of metabolic syndrome, obesity, and type 2 diabetes. In April 2024, he was granted the rank of doctor honoris causa from the King Juan Carlos University, Madrid.
Evan Dale Abel is an American endocrinologist who serves as Chair of the Department of Medicine at the David Geffen School of Medicine at UCLA. His works on the molecular mechanisms that underpin cardiac failure in diabetes. He is a Fellow of the American Heart Association and the American College of Physicians. He was elected a member of the National Academy of Sciences in 2022.
Shaodong Guo is a Chinese-American nutrition scientist, academic, and diabetes researcher. He is a professor in nutrition and medicine at the Department of Nutrition of Texas A&M University. He has been a senior editor for Journal of Endocrinology and Journal of Molecular Endocrinology.
Lee Limbird is a pharmacologist, Dean of the School of Natural Science, Mathematics and Business & Professor in the Department of Life and Physical Sciences at Fisk University, Nashville, Tennessee.
Mark Anthony Febbraio is a physiologist, academic and researcher. He is a professor and head of the Cellular and Molecular Metabolism Laboratory at the Monash Institute of Pharmaceutical Sciences (MIPS) of Monash University and a Senior Principal Research Fellow of the National Health and Medical Research Council (NHMRC).